Scienture Holdings, Inc. (SCNX) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Scienture Holdings, Inc. stock (SCNX) is currently trading at $0.46. Scienture Holdings, Inc. PE ratio is 0.65. Scienture Holdings, Inc. PS ratio (Price-to-Sales) is 30.14. Analyst consensus price target for SCNX is $1.50. WallStSmart rates SCNX as Sell.
- SCNX PE ratio analysis and historical PE chart
- SCNX PS ratio (Price-to-Sales) history and trend
- SCNX intrinsic value — DCF, Graham Number, EPV models
- SCNX stock price prediction 2025 2026 2027 2028 2029 2030
- SCNX fair value vs current price
- SCNX insider transactions and insider buying
- Is SCNX undervalued or overvalued?
- Scienture Holdings, Inc. financial analysis — revenue, earnings, cash flow
- SCNX Piotroski F-Score and Altman Z-Score
- SCNX analyst price target and Smart Rating
Scienture Holdings, Inc.
📊 No data available
Try selecting a different time range
SCNX Intrinsic Value Analysis for Value Investors
Benjamin Graham Formula · Scienture Holdings, Inc. (SCNX)
SCNX trades at a significant discount to its Graham intrinsic value of $5.10, offering a 91% margin of safety — a level value investors typically seek before buying.
Based on Benjamin Graham Formula. Growth rate capped at 25%. For informational purposes only. Not financial advice.
Smart Analysis
Scienture Holdings, Inc. (SCNX) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Scienture Holdings, Inc. (SCNX) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 810.00% year-over-year
Supporting Valuation Data
Scienture Holdings, Inc. (SCNX) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 30.1x annual revenue
Very low institutional interest at 3.72%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Scienture Holdings, Inc. (SCNX) Detailed Analysis Report
Overall Assessment
This company scores 29/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth. Valuation metrics including Price/Book (0.23) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 810.00%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (30.14) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -24.10%, Operating Margin at -739.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -24.10% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 810.00% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
SCNX Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
SCNX's Price-to-Sales ratio of 30.14x trades at a deep discount to its historical average of 68.2x (67th percentile). The current valuation is 97% below its historical high of 1150.71x set in Jan 2025, and 17629% above its historical low of 0.17x in Feb 2014. Over the past 12 months, the PS ratio has compressed from ~460.9x as trailing revenue scaled faster than the stock price.
Compare SCNX with Competitors
Top PHARMACEUTICAL RETAILERS stocks by market cap
Compare any two stocks →WallStSmart Analysis Synopsis
Data-driven financial summary for Scienture Holdings, Inc. (SCNX) · HEALTHCARE › PHARMACEUTICAL RETAILERS
The Big Picture
Scienture Holdings, Inc. is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 653,390 with 810% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Revenue growing at 810% YoY, reaching 653,390. This pace significantly outperforms most PHARMACEUTICAL RETAILERS peers.
Spending 26% of revenue (169,344) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -3M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Scienture Holdings, Inc. maintain 810%+ revenue growth, or will competition slow it down?
Sector dynamics: monitor PHARMACEUTICAL RETAILERS industry trends, competitive moves, and regulatory changes that could impact Scienture Holdings, Inc..
Bottom Line
Scienture Holdings, Inc. is a high-conviction growth story with revenue accelerating at 810% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Scienture Holdings, Inc.(SCNX)
NASDAQ
HEALTHCARE
PHARMACEUTICAL RETAILERS
USA
Scienture Holdings, Inc. (SCNX) is an innovative biotechnology company focused on developing cutting-edge therapeutic solutions for neurological disorders. With a robust drug development pipeline supported by advanced technology and a highly skilled research team, Scienture is committed to meeting unmet medical needs and improving patient outcomes. The company's strategic emphasis on scientific excellence, regulatory compliance, and collaborative partnerships positions it well for growth within the burgeoning healthcare sector, highlighting its potential to make significant contributions to global health advancements.